ASH 2020 Lymphoma In-depth

Complete Coverage

Interim Analysis Shows Benefit of First-Line Axi-Cel in High-Risk LBCL

Axi-cel demonstrated significant clinical benefit as a first-line treatment for patients with high-risk large B-cell lymphoma.

Response Rates in Phase 1 Studies of Hematologic Malignancies Improved Over Time

Response rates have improved as phase 1 studies shifted from chemotherapy to targeted agents for hematologic malignancies.

Duvelisib Had Consistent Response Rates in R/R Peripheral T-Cell Lymphoma

Response appears to be consistent across histological subtypes.

HSCT Found Potentially Curative for Some T-Cell Lymphoma Patients

A multicenter, retrospective study demonstrated higher PFS and OS rates with allogeneic transplant for relapsed/refractory TCL.

Romidepsin Plus CHOP Fails to Improve PFS in PTCL

The addition of romidepsin to CHOP did not improve PFS over CHOP alone among patients with previously untreated PTCL.

Azacitidine Plus CHOP Shows Promise for PTCL Subtype

The purpose of this study was to evaluate azacitidine in combination with CHOP in a PTCL population enriched for AITL.